Hantavirus Global Situational Briefing — July 20, 2026

Executive read

As of the 20 July 2026, 08:00 (UTC+8) cutoff, the M/V Hondius Andes-virus event remains at 13 reported cases and three deaths: 12 laboratory-confirmed infections and one probable case. WHO says all identified contacts completed 42 days of follow-up without additional secondary cases, and that the event no longer poses a public-health risk. 1

The meaningful new information today is in the clinical literature rather than in outbreak counts. Two peer-reviewed reviews newly indexed in mid-July examine neurological complications of hantavirus infection and haemostatic dysfunction in haemorrhagic fever with renal syndrome (HFRS). They sharpen clinical context across hantavirus syndromes, but they do not change the risk assessment for the closed Hondius event or establish a new outbreak anywhere.

Among the official outbreak and surveillance sources reviewed for this briefing, no new qualifying WHO, CDC, ECDC, Argentine national, or selected Asia-Pacific case report or alert escalation was verified after the previous cutoff. That is a bounded information finding, not evidence that hantavirus activity has stopped.

Signal table

Signal	Latest verified reading	Interpretation at this cutoff
M/V Hondius Andes event	13 cases, three deaths; 12 confirmed and one probable. WHO reports completed contact follow-up with no additional secondary cases detected. 1	The international response is in closure posture. Do not count this as an ongoing uncontrolled outbreak.
New clinical evidence	A JAMA Neurology review describes uncommon but potentially severe neurological manifestations; a PLOS Neglected Tropical Diseases systematic review covers haemostatic dysfunction in HFRS across 55 studies and 7,950 patients. 2 3	The papers refine syndrome and strain interpretation. They are not new case notifications or treatment approvals.
Europe / ECDC	The week 29 Communicable Disease Threats Report, published 17 July for 13–17 July, contains no hantavirus item. 4	No new ECDC hantavirus escalation appears in the latest weekly bulletin reviewed. This is not a Europe-wide zero-incidence statement.
Argentina	BEN 816, covering 28 June–4 July, remains the latest bulletin listed by Argentina's Ministry of Health. Its quick table shows 51 cumulative 2026 hantavirosis events versus a 2022–2025 median of 33; year-to-date and latest-four-week comparisons are both above expected. 5 6	This remains the main live quantitative national signal, but the data cutoff is 4 July, not 20 July.
United States	CDC's 24 June response update said all potentially exposed U.S. citizens completed 42-day monitoring without developing hantavirus disease. Preliminary rodent samples from Argentina were negative and the likely exposure source remained under investigation. 7	U.S. contact monitoring is closed; the ecological investigation is not.

What changed since the previous briefing

The official outbreak record is unchanged. ECDC's latest weekly report is still the week 29 issue, covering 13–17 July, and its public topic list includes Ebola, respiratory viruses, influenza, Vibrio, West Nile virus infections, Crimean-Congo haemorrhagic fever, cyclosporiasis, mpox, and other threats, but no hantavirus entry. The omission supports a narrow conclusion: ECDC added no new hantavirus threat item in that bulletin. It cannot provide a denominator for European hantavirus infections or exclude sporadic cases that did not meet the report's inclusion threshold. 4

The new signal is bibliographic and clinical. PubMed records list a review of neurological manifestations on 14 July and a systematic review of HFRS bleeding and haemostasis on 15 July.

Science watch: two reviews with different uses

Neurological complications remain uncommon, but can be severe

The JAMA Neurology review describes neurological involvement across hantavirus disease as poorly understood and generally uncommon. In pulmonary disease, neurological findings may arise secondarily from hypoxic or ischaemic injury or metabolic dysfunction. The review also describes meningoencephalitis and pituitary apoplexy, which can cause sudden visual loss and pituitary dysfunction, and notes rare seizures, myelitis, and peripheral neuropathy. 2

The paper does not identify an approved hantavirus-specific antiviral treatment. Its conclusion is a research and clinical-knowledge gap: prospective studies and experimental models are needed to define mechanisms, therapeutic targets, and management guidance. Severe hantavirus disease should not be conceptualised only as a pulmonary or renal syndrome when neurological findings are present. The review does not provide an incidence estimate for Andes virus in the Hondius event and should not be used to infer that neurological complications occurred among those 13 cases.

HFRS bleeding patterns differ by virus, with evidence-quality limits

The PLOS Neglected Tropical Diseases review is the more quantitative of the two. It synthesised 55 studies involving 7,950 patients with confirmed HFRS. The authors searched five databases through 12 December 2024, assessed risk of bias, and did not perform a meta-analysis because the studies and outcome reporting were too heterogeneous. 3

Thrombocytopenia was the most consistent abnormality. The review found that it was generally more pronounced in Hantaan, Dobrava, and Seoul virus infections than in Puumala infection, which was associated with milder disease. Mildly prolonged activated partial thromboplastin time and elevated D-dimer were reported variably. Paediatric evidence was limited and suggested milder disease with less pronounced coagulation abnormalities. The authors stress that variable study quality and incomplete reporting limit firm conclusions.

For surveillance, the useful point is that "HFRS" is not a single clinical phenotype. Strain identification and reporting of platelet, coagulation, and bleeding findings can change how a case is interpreted. The review should not be transferred directly to the current Hondius event: Andes virus is a New World hantavirus associated with hantavirus pulmonary syndrome, while this review focused mainly on Old World hantaviruses. It does not establish a new clinical protocol.

The closed ship event still has an open source question

WHO's final event notice remains the correct case-count anchor. As of 2 July, 13 cases were reported, including three deaths, for a 23% case-fatality ratio; 12 infections were confirmed for Andes virus and one was probable. Eight of the ten hospitalised patients had recovered and been discharged in that notice, while two were still receiving treatment at the time. Those clinical outcomes are dated to the notice and should not be carried forward as current status without a newer direct update. 1

The operational endpoint is stronger than the absence of new headlines. WHO reports that 317 high-risk contacts completed quarantine and monitoring and about 336 low-risk contacts completed self-monitoring across 33 countries and overseas territories. No additional secondary cases were detected during the 42-day follow-up. ECDC's dedicated outbreak page now says the event was declared over by WHO on 2 July and is no longer regularly updated; it retains the 12 confirmed, one probable, and three deaths count. 1 8

The source investigation remains separate. WHO says the initial infections were probably acquired on land before embarkation, but the exact source and route remain undetermined. CDC reported that preliminary rodent samples from Argentina were negative while field investigation continued. A negative preliminary sample set says what was not detected in those samples; it does not identify the reservoir or exclude a missed exposure site. 1 7

Argentina remains the live national watchpoint

The Argentina Ministry of Health index was updated on 13 July and still lists BEN 816 as the newest 2026 bulletin. The quick table's 51 cumulative hantavirosis events are above the 2022–2025 median of 33, and the bulletin marks both the year-to-date and most recent four-week comparisons as above expected. The reporting window ends on 4 July, so the figure is not a real-time 20 July count. 5 6

The signal also should not be merged with the earlier seasonal series from BEN 812, which used a different denominator and reporting frame. Nor does an above-expected calendar-year comparison establish a single national outbreak, a new hantavirus variant, or a connection to the Hondius cases. The next useful Argentine release would add geography, severe outcomes, shared exposure settings, or validated ecological and genomic findings.

Regional scan

Americas. Argentina is the only current quantitative national signal in the verified source set for this briefing. No new readable Chilean primary case-count update was located, so no Chile number is added. WHO continues to identify Argentina and Chile as endemic settings relevant to Andes virus, while genomic and ecological questions from the ship event remain open. 1

Europe. The week 29 ECDC bulletin contains no hantavirus item, and the dedicated Andes page says the ship-linked event is over with very low risk to the general EU/EEA population. This supports "no new ECDC escalation in the reviewed bulletin," not "no hantavirus infections in Europe." 4 8

United States and Asia-Pacific. CDC's monitored U.S. contacts completed follow-up without outbreak-related disease. Singapore's Ministry of Health said on 7 July that the cruise-linked outbreak had subsided and that coordinated international action had contained further spread; it did not report a Singapore case count. 7 9

Watchpoints for the next briefing

Argentina's next national or provincial release: check whether the above-expected signal persists, where it is concentrated, and whether severe outcomes or shared exposures are documented.
Clinical evidence: keep the new reviews in context. They support more careful syndrome and strain classification, but neither changes treatment guidance nor supplies current outbreak case data.
Source and reservoir work: look for validated rodent, environmental, or genomic findings from Argentina, Chile, or the international investigation. Preliminary negative trapping is not an identified source.
Official alert posture: a new WHO, PAHO, ECDC, CDC, or national-health-authority notice would change today's closure assessment. Secondary reports remain outside the case count until a primary source confirms them.

The 20 July assessment is stable but not empty. The ship-linked Andes event remains closed at 13 cases and three deaths. Argentina's latest available national table is still above expected, but ends on 4 July. Two new clinical reviews add detail on neurological complications and HFRS haemostasis without changing the outbreak picture. The next material shift is most likely to come from an Argentine surveillance update, a validated source-investigation result, a direct clinical follow-up, or a new official alert.